Wave Life Sciences, Inc. (WVE)
Nasdaq · Pharmaceutical Preparations · Manufacturing · CIK 1631574 · fiscal year ends in Dec
Closing price $3.63 on 29 Oct 2026; 52-week range $3.07 to $21.31.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $70.9M
- Net income, last twelve months
- -$210.5M
- Earnings per share
- -$1.07
- Operating margin
- -320.9%
- Net margin
- -296.9%
- Return on equity
- -52.4%
- Market value
- $714.9M
- Cash
- $197.3M
- Debt
- $0
- Debt to equity
- 0.00
- Shares outstanding
- 197.2M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $42.7M | -$215.4M | -$204.4M | -$1.21 | -$188.2M | 10-K filed 26 Feb 2026 |
| FY2024 | 31 Dec 2024 | $108.3M | -$110.4M | -$97.0M | -$0.70 | -$152.0M | 10-K filed 4 Mar 2025 |
| FY2023 | 31 Dec 2023 | $113.3M | -$68.0M | -$57.5M | -$0.54 | -$20.5M | 10-K filed 6 Mar 2024 |
| FY2022 | 31 Dec 2022 | $3.6M | -$162.7M | -$161.8M | -$2.05 | -$129.1M | 10-K filed 23 Mar 2023 |
| FY2021 | 31 Dec 2021 | $41.0M | -$127.0M | -$122.2M | -$2.36 | -$89.6M | 10-K filed 3 Mar 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q3 FY2026 | 30 Sep 2026 | $13.2M | -$61.9M | -$0.30 |
| Q2 FY2026 | 30 Jun 2026 | $2.3M | -$69.4M | -$0.34 |
| Q1 FY2026 | 31 Mar 2026 | $38.2M | -$26.1M | -$0.13 |
| Q4 FY2025 | 31 Dec 2025 | $17.2M | -$53.2M | -$0.30 |
| Q3 FY2025 | 30 Sep 2025 | $7.6M | -$53.9M | -$0.32 |
| Q2 FY2025 | 30 Jun 2025 | $8.7M | -$50.5M | -$0.31 |
| Q1 FY2025 | 31 Mar 2025 | $9.2M | -$46.9M | -$0.29 |
| Q2 FY2024 | 30 Jun 2024 | $19.7M | -$32.9M | -$0.25 |
Company events
The newest 8-K filings of 161 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 27 Oct 2026 | 8-K | Results | 2.02, 9.01 |
| 7 Aug 2026 | 8-K12B | Change in control, Leadership change, Material agreement, Share sale, Shareholder rights change, Bylaws or fiscal year change, Other events | 1.01, 3.02, 3.03, 5.01, 5.02, 5.03, 8.01, 9.01 |
| 30 Jul 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 26 Jun 2026 | 8-K | Shareholder vote | 5.07 |
| 18 May 2026 | 8-K | Investor update, Other events | 7.01, 8.01, 9.01 |
| 28 Apr 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 21 Apr 2026 | 8-K | Other events | 8.01, 9.01 |
| 15 Apr 2026 | 8-K | Material agreement, Other events | 1.01, 8.01, 9.01 |
| 26 Mar 2026 | 8-K | Investor update, Other events | 7.01, 8.01, 9.01 |
| 26 Feb 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 2 Feb 2026 | 8-K | Other events | 8.01, 9.01 |
| 12 Jan 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
Every filing
The newest filings with the SEC of 324 held.
| Filed | Form | Period |
|---|---|---|
| 27 Oct 2026 | 10-Q | 30 Sep 2026 |
| 27 Oct 2026 | 8-K | 27 Oct 2026 |
| 14 Oct 2026 | ARS | 31 Dec 2025 |
| 14 Oct 2026 | DEF 14A | 12 Nov 2026 |
| 14 Aug 2026 | EFFECT | – |
| 10 Aug 2026 | 15-12G | – |
| 10 Aug 2026 | POS AM | – |
| 10 Aug 2026 | POSASR | – |
| 10 Aug 2026 | S-8 POS | – |
| 10 Aug 2026 | S-8 POS | – |
| 10 Aug 2026 | S-8 POS | – |
| 10 Aug 2026 | S-8 POS | – |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 12 Aug 2026 | Rawcliffe Adrian, Director | Sale under a trading plan | 12,700 | $5.29 | $67.2K | 0 | 13 Aug 2026 |
| 11 Aug 2026 | Wagner Heidi L, Director | Sale under a trading plan | 7,000 | $6.01 | $42.1K | 44,930 | 13 Aug 2026 |
| 11 Aug 2026 | Takanashi Ken, Director | Sale under a trading plan | 3,864 | $6.01 | $23.2K | 20,079 | 13 Aug 2026 |
| 11 Aug 2026 | Tan Aik Na, Director | Sale under a trading plan | 432 | $6.01 | $2.6K | 24,968 | 13 Aug 2026 |
| 30 Mar 2026 | Ra Capital Management, L.P., Director | Purchase | 971,091 | $6.50 | $6.3M | 26,975,505 | 30 Mar 2026 |
| 27 Mar 2026 | Ra Capital Management, L.P., Director | Purchase | 2,495,623 | $6.43 | $16.0M | 26,004,414 | 30 Mar 2026 |
| 26 Mar 2026 | Ra Capital Management, L.P., Director | Purchase | 4,954,558 | $6.06 | $30.0M | 23,157,567 | 30 Mar 2026 |
| 26 Mar 2026 | Ra Capital Management, L.P., Director | Purchase | 351,224 | $6.38 | $2.2M | 23,508,791 | 30 Mar 2026 |
| 26 Feb 2026 | Francis Chris, See Remarks | Sale under a trading plan | 17,900 | $15.09 | $270.2K | 61,867 | 27 Feb 2026 |
| 26 Feb 2026 | Francis Chris, See Remarks | Sale under a trading plan | 15,294 | $15.00 | $229.4K | 61,867 | 27 Feb 2026 |
| 9 Feb 2026 | Moran Kyle, Chief Financial Officer | Sale outside a trading plan | 3,588 | $13.45 | $48.3K | 134,385 | 11 Feb 2026 |
| 9 Feb 2026 | Bolno Paul, President and CEO | Sale outside a trading plan | 10,480 | $13.45 | $141.0K | 275,520 | 11 Feb 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 12 Aug 2026 | ADRIAN G RAWCLIFFE, Director | 12,700 | $64.1K | 12 Aug 2026 |
| 11 Aug 2026 | HEIDI L WAGNER, Director | 7,000 | $42.5K | 11 Aug 2026 |
| 9 Feb 2026 | Chris Francis, Officer | 1,870 | $25.2K | 9 Feb 2026 |
| 9 Feb 2026 | KYLE MORAN, Officer | 3,564 | $47.9K | 9 Feb 2026 |
| 9 Feb 2026 | PAUL BOLNO, Officer | 10,411 | $140.0K | 9 Feb 2026 |
| 9 Dec 2025 | KYLE MORAN, Officer | 86,000 | $1.6M | 9 Dec 2025 |
| 8 Dec 2025 | HEIDI L WAGNER, Director | 14,000 | $104.9K | 8 Dec 2025 |
| 8 Dec 2025 | MARK CORRIGAN, Director | 16,115 | $120.7K | 8 Dec 2025 |
| 8 Dec 2025 | GREGORY VERDINE, Director | 20,000 | $149.8K | 8 Dec 2025 |
| 8 Dec 2025 | ADRIAN RAWCLIFFE, Director | 42,000 | $314.6K | 8 Dec 2025 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 27 Oct 2026 | BlackRock, Inc. | 13G | 6.8% | 13.4M |
| 27 Oct 2026 | BlackRock, Inc. | 13G amended | 0% | 0 |
| 11 Aug 2026 | RA Capital Management, L.P. | 13D amended | 16.8% | 34.3M |
| 13 May 2026 | Adage Capital Management, L.P. | 13G amended | 0.53% | 1.0M |
| 6 May 2026 | FMR LLC | 13G amended | 2.8% | 5.2M |
| 17 Apr 2026 | RA Capital Management, L.P. | 13D amended | 17.1% | 34.2M |
| 30 Mar 2026 | RA Capital Management, L.P. | 13D amended | 17.5% | 34.2M |
| 12 Feb 2026 | Adage Capital Management, L.P. | 13G amended | 5.35% | 9.8M |
| 5 Feb 2026 | FMR LLC | 13G | 8.5% | 15.0M |
| 15 Dec 2025 | RA Capital Management, L.P. | 13D amended | 13.4% | 25.5M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 21.2M | +14.07% | 6.53 |
| 30 Sep 2026 | 18.6M | +5.21% | 5.7 |
| 15 Sep 2026 | 17.6M | +8.33% | 5.17 |
| 31 Aug 2026 | 16.3M | +0.5% | 5.49 |
| 14 Aug 2026 | 16.2M | -1.22% | 4.39 |
| 31 Jul 2026 | 16.4M | -2.65% | 7.45 |
| 15 Jul 2026 | 16.8M | -19.39% | 6.3 |
| 30 Jun 2026 | 20.9M | +15.14% | 5.68 |
Funds that hold it
From each fund's latest Form 13F.
279 funds held it at 30 Jun 2026: 146 added and 53 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Ra Capital Management, L.P. | 26,975,505 | $156.7M | 0 |
| BlackRock, Inc. | 19,202,461 | $111.6M | +5,085,049 |
| GSK plc | 18,245,691 | $106.0M | 0 |
| Maverick Capital Ltd | 10,278,115 | $59.7M | +116,716 |
| Driehaus Capital Management LLC | 5,443,143 | $31.6M | +12,122 |
| Primecap Management Co. | 5,354,622 | $31.1M | +521,670 |
| 683 Capital Management, LLC | 4,950,000 | $28.8M | +50,000 |
| FMR LLC | 4,922,477 | $28.6M | -270,284 |
| State Street Corp. | 4,839,317 | $28.1M | +1,165,284 |
| Readystate Asset Management LP | 4,727,139 | $27.5M | +4,727,139 |
Peers
Companies in the same industry.
- Eli Lilly & Co. (LLY): revenue $86.5B, market value $1.29T
- Johnson & Johnson (JNJ): revenue $99.3B, market value $662.4B
- AbbVie Inc. (ABBV): revenue $64.4B, market value $513.9B
- Merck & Co., Inc. (MRK): revenue $66.6B, market value $361.0B
- Novartis AG (NVS): revenue $54.5B, market value $307.3B
- AstraZeneca PLC (AZN): revenue $58.7B, market value $270.6B
- Abbott Laboratories (ABT): revenue $46.6B, market value $180.9B
- Novo Nordisk A/S (NVO): revenue $46.8B, market value $174.8B
- Pfizer Inc. (PFE): revenue $63.7B, market value $170.7B
- Vertex Pharmaceuticals Inc. (VRTX): revenue $12.6B, market value $136.8B